A Study of the First-line Treatment of Patients With Newly Diagnosed Transplant-ineligible Multiple Myeloma in Spain
Launched by CELGENE · Jul 18, 2018
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged ≥ 18 years
- • Patients with newly diagnosed MM who were not suitable candidates for ASCT who started anti-myeloma treatment between 2012 and 2016, inclusive.
- • Patients who give informed consent before data collection begins.
- Exclusion Criteria:
- • Patients who participated in a clinical trial for first-line treatment of MM during the study period.
- • Patients who are alive, but do not give their IC.
- • Patients with MM who did not receive treatment.
About Celgene
Celgene, now a part of Bristol Myers Squibb, is a global biopharmaceutical company dedicated to advancing innovative therapies for patients with cancer and other serious diseases. With a strong emphasis on research and development, Celgene focuses on discovering and delivering transformative medicines that address unmet medical needs. The company is committed to enhancing patient outcomes through rigorous clinical trials, cutting-edge science, and collaboration with healthcare professionals, ultimately striving to improve the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Malaga, , Spain
Valencia, , Spain
Sevilla, , Spain
L'hospitalet De Llobregat, Barcelona, Spain
Santiago De Compostela, A Coruña, Spain
Vitoria, Alava, Spain
Gijón, Asturias, Spain
Oviedo, Asturias, Spain
Palma, Baleares, Spain
Manresa, Barcelona, Spain
Terrasa, Barcelona, Spain
Jerez De La Frontera, Cadiz, Spain
Vigo, Pontevedra, Spain
Barcelona, , Spain
Girona, , Spain
Lleida, , Spain
Malaga, , Spain
Orense, , Spain
Tarragona, , Spain
Valencia, , Spain
Patients applied
Trial Officials
Giselle Lostaunau, MD
Study Director
Celgene
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials